Generated by All in One SEO Pro v4.9.6.2, this is an llms.txt file, used by LLMs to index the site.

# Opus Genetics

## Sitemaps

- [XML Sitemap](http://dev-opustx.pantheonsite.io/sitemap.xml): Contains all public & indexable URLs for this website.

## Pages

- [Home](http://dev-opustx.pantheonsite.io/) - Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing important new therapies for the treatment of IRDs and other retinal and refractive disorders.
- [About](http://dev-opustx.pantheonsite.io/about/) - Advancing First-in-Class Gene Therapies for Inherited Retinal Diseases Opus Genetics is a clinical-stage ophthalmic biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company’s mission is to design therapies to address the underlying genetic causes of severe retinal disorders that deliver durable vision improvement for
- [Patients & Families](http://dev-opustx.pantheonsite.io/patients-and-families/) - For Patients & Families Watch the Documentary on Opus Genetics patient Lindsey Rambo At Opus Genetics, our mission begins and ends with you—the patients and families living with inherited retinal diseases (IRDs). We believe sight is worth fighting for, and everyone deserves the chance to see what makes life beautiful. Together with scientists, doctors, and most
- [Gene Therapies](http://dev-opustx.pantheonsite.io/gene-therapies/) - Our Approach It’s estimated that over 300,000 patients are waiting for treatments for their individual genetic conditions, and more than 350 genes are known to cause inherited retinal diseases. Opus Genetics’ mission is to pave a proven, derisked, efficient path to the clinic for urgently needed new therapies. Our IRD programs address mutations in genes
- [Pipeline](http://dev-opustx.pantheonsite.io/pipeline/) - Advancing a Diversified Portfolio of First-in-Class Gene Therapies
- [Contact Us](http://dev-opustx.pantheonsite.io/contact-us/) - Opus Genetics 8 Davis DriveDurham, NC 27713 To receive email alerts from Opus, register here. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
- [Careers](http://dev-opustx.pantheonsite.io/careers/) - Careers at Opus At Opus Genetics, our mission is to restore and preserve vision for patients with inherited retinal diseases. We’re a growing, hands-on team that values ownership, curiosity, and momentum. Everyone at Opus plays a meaningful role, whether advancing breakthrough science, shaping clinical strategy, or supporting the teams that make progress possible. If you’re

## Patient Stories

- [Lindsey Rambo, LCA5 Patient](http://dev-opustx.pantheonsite.io/patient-stories/lindsey-rambo/) - Lindsey’s life has been shaped by vision loss from an early age, later identified as LCA5, a rare inherited retinal condition. Growing up, she often struggled to understand why she was different, navigating everyday situations with limited sight while trying to fit in. Simple tasks required extra effort, and the uncertainty surrounding her condition made

## Pipeline

- [OPGx-LCA5](http://dev-opustx.pantheonsite.io/pipeline/opgx-lca5/)
- [OPGx-BEST1](http://dev-opustx.pantheonsite.io/pipeline/opgx-best1/)

## Team Member

- [Cam Gallagher, MBA](http://dev-opustx.pantheonsite.io/about/board/cam-gallagher-mba/) - Cam Gallagher has more than 30 years of experience in the life science and biotech industry with a focus on new company formation, corporate development, marketing, operations, and early-stage investing. Mr. Gallagher has served as a member of the Ocuphire (now Opus) Board since January 2019 and Chair since December 2019. He currently is President,
- [Sarah Tuller, JD](http://dev-opustx.pantheonsite.io/about/leadership/sarah-tuller-jd/) - Sarah Tuller has 25 years of experience in regulatory strategy and operations, spanning numerous clinical and commercial-stage products across a wide range of therapeutic indications, including multiple cell and gene therapies and orphan disease programs. She has led or been a part of numerous successful IND, NDA, MAA and BLA applications, including those of Portrazza®
- [Jean Bennett, MD, PhD](http://dev-opustx.pantheonsite.io/about/leadership/jean-bennett-md-phd/) - Dr. Bennett is the F.M. Kirby Emeritus Professor of Ophthalmology at the Perelman School of Medicine and previously served as director of the Center for Advanced Retinal and Ocular Therapeutics (CAROT) at the University of Pennsylvania. In addition to Dr. Bennett’s positions at the University of Pennsylvania, she has been an Investigator at the Center
- [Chris Ernst](http://dev-opustx.pantheonsite.io/about/leadership/chris-ernst/) - Chris has more than 30 years in industry, with a background that includes laboratory operations management of environmental, cGMP, clinical, and non-clinical GLP services, as well as phase I-IV clinical research and oversight including small molecules, proteins, biologics and monoclonal antibodies, gene therapy AAV’s, combination products, and medical devices. Since 2013, he has worked in
- [Sally Tucker, PhD](http://dev-opustx.pantheonsite.io/about/leadership/sally-tucker-phd/) - Sally Tucker, an independent prescribing optometrist with a PhD in ophthalmology and master’s in business management, has more than 20 years’ experience within the ophthalmology sector. Sally joined the ophthalmology industry in 2003 with her career spanning across sales & marketing, training, medical affairs and clinical. Her expertise and special interest include all phases of
- [Ash Jayagopal, PhD, MBA](http://dev-opustx.pantheonsite.io/about/leadership/ash-jayagopal-phd-mba/) - Dr. Jayagopal is a bioengineer by training with over 15 years of experience leading multidisciplinary research teams focused on therapeutic research and development, drug delivery platforms, and biomarkers for retinal diseases in industry and academia. Ash oversees research and development strategy for Opus, including the execution of IRD clinical trials and pipeline development for retinal
- [Joe Schachle, MBA](http://dev-opustx.pantheonsite.io/about/leadership/joe-schachle-mba/) - Mr. Schachle brings more than 30 years of experience in life sciences to his role as Chief Operating Officer of Opus, with specific expertise in strategic and operational planning, business development, marketing and sales, and business intelligence. Before joining Opus, Mr. Schachle served as vice president of Customer Experience Enablement and vice president of global
- [Robert Gagnon, CPA, MBA](http://dev-opustx.pantheonsite.io/about/leadership/robert-gagnon-cpa-mba/) - Mr. Gagnon is an accomplished biotech executive with more than two decades of financial and operational leadership experience in both public and private companies. He has raised over $2 billion in capital, executed multiple strategic transactions, and held senior roles guiding companies through IPOs, late-stage clinical development, commercial launches, and M&A. He joins Opus from
- [Ben Yerxa, PhD](http://dev-opustx.pantheonsite.io/about/leadership/ben-yerxa-phd/) - Dr. Yerxa currently serves as Opus Genetics’ President since October, 2024. Dr. Yerxa was Chief Executive Officer and President of Opus from September, 2021. Dr. Yerxa previously served as Chief Executive Officer of the Foundation Fighting Blindness (“FFB”) starting in October 2017, a foundation that drives research to provide treatments and cures for people affected
- [Adrienne Graves, PhD](http://dev-opustx.pantheonsite.io/about/board/adrienne-graves-phd/) - Dr. Adrienne Graves is a visual scientist by training and a global industry leader in ophthalmology. Dr. Graves was CEO of Santen Inc (2002-2010) following 7 years there as Sr VP of Worldwide Clinical Development. She previously spent 9 years at Alcon, where she built a Retinal Electrophysiology Lab, directed clinical development and served as
- [Ben Yerxa, PhD](http://dev-opustx.pantheonsite.io/about/board/ben-yerxa-phd-2/) - Dr. Yerxa currently serves as Opus Genetics’ President since October, 2024. Dr. Yerxa was Chief Executive Officer and President of Opus from September, 2021. Dr. Yerxa previously served as Chief Executive Officer of the Foundation Fighting Blindness (“FFB”) starting in October 2017, a foundation that drives research to provide treatments and cures for people affected
- [George Magrath, MD, MBA, MS](http://dev-opustx.pantheonsite.io/about/leadership/george-magrath-md-mba-ms/) - Dr. Magrath, MD, currently serves as Chief Executive Officer and a Board member of Opus Genetics, which was recently acquired by Ocuphire Pharma during his tenure there as CEO. Dr. Magrath is a board-certified ophthalmologist with extensive clinical, business, and financial experience. Most recently, Dr. Magrath was CEO of Lexitas Pharma Services, a leading contract
- [Richard Rodgers, MBA](http://dev-opustx.pantheonsite.io/about/board/richard-rodgers-mba/) - Richard Rodgers has served on our Board since November 2020 and served as our Interim Chief Executive Officer and President from April 2023 through October 2023. Prior to his appointment as Interim Chief Executive Officer and President in April 2023, Mr. Rodgers served as chair of the Audit Committee and member of the Compensation Committee
- [James Manuso, PhD, MBA](http://dev-opustx.pantheonsite.io/about/board/james-manuso-phd-mba/) - James S. Manuso, Ph.D., M.B.A., Chairman and CEO of Talfinium Investments, Inc., and Chairman of TuHura Biosciences Inc (Nasdaq:HURA) has served on the Ocuphire (now Opus) Board since January 2019. Dr. Manuso served as an international biotechnology/pharmaceutical industry CEO and management consultant for over 30 years. He co-founded multiple biotech companies where he held C-level
- [Susan Benton, MBA](http://dev-opustx.pantheonsite.io/about/board/susan-benton-mba/) - Ms. Susan Benton is a strategic business consultant and owner of i2eye Consulting, LLC. Since July 2024, she has been a strategic advisor and consultant to six ophthalmic start-up companies. In addition to consulting, she joined the Ocuphire (now Opus) Board in November 2020, and she also sits on the boards of Tarsier Pharma since
- [Sean Ainsworth, MBA](http://dev-opustx.pantheonsite.io/about/board/sean-ainsworth-mba/) - Sean Ainsworth is Chief Executive Officer and Chairman of the Board at Immusoft, a Seattle-based cell therapy company, and has 25 years of experience in pharmaceuticals and biotechnology. Mr. Ainsworth has served as a member of the Ocuphire (now Opus) Board since April 2018 and currently serves as the Lead Independent Director of the Board.He